However, the study yielded a notable exposure-response relationship, with Eldelumab clinical response and mucosal healing rates being greatest in patients with the highest trough concentrations.68 We have observed similar outcomes in a trial of NI-0801, a monoclonal antibody against CXCL10, in patients with the immune-mediated liver disease primary biliary cholangitis (PBC), which suggests that the high production rate of CXCL10 by inflamed tissues makes it difficult to achieve therapeutic drug levels and sustained neutralisation of the chemokine in vivo (K. de Graaf et al; submitted). This evidence concerns the gene CXCL10 and biliary liver cirrhosis.